Literature DB >> 241143

Bone marrow transplantation in the busulfan-treated rat. I. Effect of cyclophosphamide and rabbit antirat thymocyte serum as immunosuppression.

P J Tutschka, G W Santos.   

Abstract

It was previously shown that lethal doses of busulfan (BU) were not immunosuppressive in the rat. In the present studies the effect of rabbit antirat thymocyte serum (RARTS) and cyclophosphamide (CY) as immunosuppressive preparation for marrow allografts in the rat given supralethal doses of BU was investigated. Lewis or LBNF rats were given RARTS for 4-12 consecutive daily doses. They were given a supralethal dose of BU in addition on the last day of RARTS administration. Ag-B-incompatible (ACI). Ag-B-compatible (F344), or syngeneic marrow was infused 24 hr later. In general, RARTS was not toxic to the marrow graft and permitted engraftment of Ag-B-incompatible and compatible marrow. All animals given Ag-B-incompatible marrow and Ag-B-compatible marrow that survived to day 21 were shown to be chimeric, but all those with incompatible marrow subsequently died from severe graft-versus-host disease (GVHD). In other experiments Lewis or LBNF1 rats were given Ag-B-incompatible (ACI) and compatible (F344) marrow after a supralethal dose of BU and single graded doses of CY. Doses of CY as low as 25-50 mg/kg provided sufficient immunosuppression to allow allogeneic engraftment. Transient chimerism was seen up to doses of 100 mg/kg of CY. Permanent chimerism was seen with doses of CY from 150 to 250 mg/kg. The incidence of lethal GVHD increased in parallel with the percentage of animals that were demonstrated to be chimeric. Mild but transient GVHD was seen with Ag-B-compatible marrow given to Lewis rats.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241143     DOI: 10.1097/00007890-197508000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Cyclosporin A -- a new outlook for immunosuppresion in clinical transplantation.

Authors:  P J Tutschka
Journal:  Blut       Date:  1979-08

2.  Ifosfamide and ACNU in experimental allogeneic bone marrow transplantation.

Authors:  W Gassmann; A Erbersdobler; L Uharek; B Glass; H Löffler; W Mueller-Ruchholtz
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.

Authors:  H P Bhagwatwar; S Phadungpojna; D S Chow; B S Andersson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells.

Authors:  Luis Graca; Alain Le Moine; Chun-Yen Lin; Paul J Fairchild; Stephen P Cobbold; Herman Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-24       Impact factor: 11.205

5.  Use of Busulfan to Condition Mice for Bone Marrow Transplantation.

Authors:  Encarnacion Montecino-Rodriguez; Kenneth Dorshkind
Journal:  STAR Protoc       Date:  2020-11-06

6.  Immune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantation.

Authors:  Severin Zinöcker; Ralf Dressel; Xiao-Nong Wang; Anne M Dickinson; Bent Rolstad
Journal:  Front Immunol       Date:  2012-11-30       Impact factor: 7.561

7.  Bone marrow transplantation: current results in leukemia.

Authors:  G W Santos
Journal:  Yale J Biol Med       Date:  1982 Sep-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.